These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19794285)

  • 21. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
    Fahrleitner-Pammer A; Piswanger-Soelkner JC; Pieber TR; Obermayer-Pietsch BM; Pilz S; Dimai HP; Prenner G; Tscheliessnigg KH; Hauge E; Portugaller RH; Dobnig H
    J Bone Miner Res; 2009 Jul; 24(7):1335-44. PubMed ID: 19257824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis.
    McCloskey E; Selby P; de Takats D; Bernard J; Davies M; Robinson J; Francis R; Adams J; Pande K; Beneton M; Jalava T; Löyttyniemi E; Kanis JA
    Bone; 2001 Mar; 28(3):310-5. PubMed ID: 11248662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
    Di Somma C; Colao A; Pivonello R; Klain M; Faggiano A; Tripodi FS; Merola B; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 1998 May; 48(5):655-62. PubMed ID: 9666879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
    Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.
    Haderslev KV; Tjellesen L; Sorensen HA; Staun M
    Am J Clin Nutr; 2002 Aug; 76(2):482-8. PubMed ID: 12145026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V; Briot K; Roux C; Roy C; Seksik P; Charachon A; Bouhnik Y; Coffin B; Allez M; Lamarque D; Chaussade S
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
    Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis.
    Osella G; Reimondo G; Peretti P; Alì A; Paccotti P; Angeli A; Terzolo M
    J Clin Endocrinol Metab; 2001 Feb; 86(2):604-7. PubMed ID: 11158016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
    Floreani A; Carderi I; Ferrara F; Rizzotto ER; Luisetto G; Camozzi V; Baldo V
    Dig Liver Dis; 2007 Jun; 39(6):544-8. PubMed ID: 17416215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer.
    Rizzoli R; Forni M; Schaad MA; Slosman DO; Sappino AP; Garcia J; Bonjour JP
    Bone; 1996 Jun; 18(6):531-7. PubMed ID: 8805993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women.
    Tsai KS; Hsu SH; Yang RS; Cheng WC; Chieng PU
    Calcif Tissue Int; 1999 May; 64(5):384-8. PubMed ID: 10203414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
    Cummings SR; Black DM; Thompson DE; Applegate WB; Barrett-Connor E; Musliner TA; Palermo L; Prineas R; Rubin SM; Scott JC; Vogt T; Wallace R; Yates AJ; LaCroix AZ
    JAMA; 1998 Dec 23-30; 280(24):2077-82. PubMed ID: 9875874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bone loss is more severe in younger Cushing's syndrome women than in older ones: comparison of bone mineral density between Cushing's syndrome and healthy women].
    Jiang Y; Meng XW; Lu ZL; Xia WB; Xing XP; Li M; Wang O; Yu W; Tian JP
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1695-7. PubMed ID: 17825152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY; Kang MI; Park HM; Rhee Y; Moon SH; Yoon HK; Koh JM; Chang JS; Kim IJ; Won YY; Park YS; Choi H; Shin CS; Yoon TR; Yun SC; Chung HY;
    Arch Osteoporos; 2019 Dec; 15(1):3. PubMed ID: 31820121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporotic vertebral compression fractures caused by Cushing's syndrome in young women: case report and literature review.
    Cheng J; Ju S; Zhang Z
    BMC Musculoskelet Disord; 2023 Mar; 24(1):167. PubMed ID: 36879208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.